A significant change within one group does not prove a significant advantage over another group.
The randomized thoracic-surgery trial compared arterial oxygenation under remimazolam and sevoflurane. At the primary thirty-minute one-lung-ventilation point, mean oxygen values did not clearly differ. A later within-group change and a lactate interaction provided secondary findings.
The sample and selected thoracic setting limit generalization. Oxygenation, lactate and clinical pulmonary outcomes are different endpoints. The presence of a significant within-group change in only one arm is not itself a test of the between-group difference.
Retain the primary result when discussing proposed metabolic advantages. The study cannot establish that remimazolam prevented hypoxic injury in an individual. Review ventilation settings, blood gases, hemodynamics and other interventions rather than interpreting a biomarker pattern as a proven protective mechanism.
Source: PMC12660034, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Remimazolam During Cardiopulmonary Bypass: A Successful Case Is a Feasibility Observation.